Journey Medical Corporation
DERM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | 0.31 | 0.03 | 0.00 |
| FCF Yield | -11.42% | 0.23% | -99.63% | -13.08% |
| EV / EBITDA | -10.16 | 49.61 | -1.06 | -1.62 |
| Quality | ||||
| ROIC | -30.00% | -5.78% | -66.67% | -70.90% |
| Gross Margin | 62.81% | 66.33% | 58.23% | 49.18% |
| Cash Conversion Ratio | 0.62 | -1.36 | 0.46 | 0.05 |
| Growth | ||||
| Revenue 3-Year CAGR | -8.66% | 7.84% | 18.27% | 21.82% |
| Free Cash Flow Growth | -3,902.92% | 100.72% | -175.30% | -409.79% |
| Safety | ||||
| Net Debt / EBITDA | -0.64 | -5.05 | 0.39 | 1.22 |
| Interest Coverage | -5.07 | -1.22 | -13.63 | -4.96 |
| Efficiency | ||||
| Inventory Turnover | 1.45 | 2.61 | 2.17 | 3.25 |
| Cash Conversion Cycle | 38.22 | -38.58 | -130.94 | -13.71 |